Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ovid Therapeutics Inc (NQ: OVID )

1.110 +0.060 (+5.71%)
Streaming Delayed Price Updated: 11:55 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ovid Therapeutics Inc

< Previous 1 2 3 4 Next >
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics to Host Investor Event
KCC2 Download Day on Wednesday, November 13, 2024 
From Ovid Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin
From Ovid Therapeutics Inc.
Via GlobeNewswire
Expert Outlook: Ovid Therapeutics Through The Eyes Of 7 Analysts
Via Benzinga
The Latest Analyst Ratings For Ovid Therapeutics
Via Benzinga
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics to Present at Upcoming September Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
OVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q2 2024
OVID stock results show that Ovid Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Evaluating Ovid Therapeutics: Insights From 6 Financial Analysts
Via Benzinga
Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer
From Ovid Therapeutics Inc.
Via GlobeNewswire
OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Ovid Therapeutics to Present at Upcoming August Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
Group to Advise on the Application of Ovid’s Novel Pipeline Programs to Broader Disorders of the Brain 
From Ovid Therapeutics Inc.
Via GlobeNewswire
7 Sorry Biotech Stocks Set to Make Investors Sad
Biotech stocks can be extremely challenging because it takes a long time to bring a therapy to market. Here are some biotech stocks to sell. 
Via InvestorPlace
eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
From Ovid Therapeutics Inc.
Via GlobeNewswire
Nasdaq Surges Over 200 Points; Aaron's Shares Jump
Via Benzinga
Is the Stock Market Closed on Juneteenth 2024?
Investors wondering if the stock market is closed on Juneteenth 2024 have come to the right place as we have an answer to that question! 
Via InvestorPlace
ACHR Stock Alert: Archer Aviation Strikes New Deal With Signature Aviation
Archer Aviation stock is down on Monday after the company alerted ACHR investors to a new MOU signed with Signature Aviation. 
Via InvestorPlace
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
AAN Stock Alert: The Aaron’s Company Pops 33% on Take-Private Deal
The Aaron's Company stock is up on Monday after it announced a take-private deal that values AAN shares at $10.10 each. 
Via InvestorPlace
Why Is Ovid Therapeutics (OVID) Stock Down 69% Today?
Ovid Therapeutics stock is down on Monday with heavy trading of OVID shares after the company reported a failed Phase3 clinical trial. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Rises 1%; Mustang Bio Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
US Stocks Mixed; Dow Tumbles Over 100 Points
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
Takeda Pharmaceutical reveals Phase 3 study data for Soticlestat (TAK-935) in treating Dravet and Lennox-Gastaut syndromes. In 2021, Ovid Therapeutics out licensed the drug. 
Via Benzinga
Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.